Profusa, a digital health company specializing in continuous biochemical monitoring, received approval from the Nasdaq Hearings Panel to transfer its stock listing from The Nasdaq Global Market to The Nasdaq Capital Market. This move is conditional on Profusa meeting certain interim milestones and complying with bid price and stockholders' equity requirements by July 6, 2026. The company focuses on innovative biosensors and data platforms for personalized medical data. This transition aims to maintain its Nasdaq listing while it works on meeting financial standards.
Ethereum's price is under pressure with technical indicators signaling a possible short-term decline. Key support around $1,800 is critical; if it breaks, the market could see further losses. High leverage and positive funding rates show many long po...
DEXE surged 13% after breaking key weekly resistance levels, signaling a shift from consolidation to expansion. The move is supported by a 12% rise in trading volume to $33 million, indicating genuine demand rather than a short spike. Significant wha...
The S&P 500 achieved its longest weekly winning streak since 2023, rising nearly 20% from March lows, supported by hopes of a U.S.-Iran ceasefire extension. Brent crude stabilized near $92 a barrel, and Treasuries recovered some losses. However, majo...
Security experts warn that Bitcoin faces urgent risks from quantum computing, which could break its cryptography much sooner than expected. A recent Google Quantum AI paper reduced the estimated quantum resources needed to crack Bitcoin's security by...
Venture capitalist Andrew Gault highlights that Bitcoin's biggest quantum risk is not its wallet keys but the encrypted authentication data exchanged between financial institutions today. Adversaries are collecting this data now to decrypt it later w...
